Hints and tips:
Related Topics
...revenues from its so-called Essential Health unit — which includes legacy brands like Lipitor and Viagra, that have already lost or will soon lose market exclusivity — “primarily due to continued legacy Hospira...
...One unit will be for high-growth products including its Hospira biosimilars group, another for off-patent treatments and a third for the over-the-counter business which it recently tried and failed to sell...
...Ian Read, chief executive, said the results were “solid” but that the company’s Essential Health business — which makes its older, off-patent medicines — had been hurt by supply shortages at Hospira, the...
...The Californian company, which acquired Hospira Infusion pumps from Pfizer in 2017, serves similar markets. The share price rise that greeted the news was justifiably muted at 2 per cent....
...ICU is in the process of integrating its $900m acquisition of Hospira Infusion Systems last year from Pfizer, a business that Smiths had also been interested in purchasing....
...Pfizer, which sold the Hospira Infusion business to ICU Medical in February 2017, said it was co-ordinating with the new owner to “produce records for the DoJ”....
...The EpiPen shortage comes as Pfizer races to resolve shortages caused by manufacturing problems at several of its factories, many of them acquired when it took over Hospira, a maker of injectable drugs,...
...Without last year’s acquisition of Hospira, sales would be falling. Patent troubles continue. Lyrica, a drug for neuropathic pain, contributes 7 per cent of sales and loses its patent in 2018....
...The drugmaker said it expected revenues to be about $50bn in 2016, excluding sales from recently acquired Hospira, flat on last year and about $2.5bn lower than analysts had typically been expecting....
...The top-five list included the addition of Oracle, which ousted Pfizer after the pharmaceuticals group completed its $17bn takeover of Hospira....
...Allergan, the maker of Botox, has itself already been involved in more than $110bn of deals in the past 12 months and Pfizer is fresh from a $17bn acquisition of Hospira and a failed $100bn pursuit of AstraZeneca...
...He has recruited Mike Ball, former chief executive of Hospira, the US drugmaker recently acquired by Pfizer, to replace Jeff George as head of Alcon and set him a target to return the unit to growth by the...
...Hospira, a maker of injectable drugs, is being acquired by Pfizer in a transaction that is expected to be completed on or about that date....
...Celltrion is seeking US approval for the drug along with its partner Hospira, which is being bought by Pfizer....
...Pfizer’s $17bn acquisition of Hospira made it one of the top makers of sterile injectable drugs, while its partnership with Merck of Germany enabled the company to gain ground in the race to develop a new...
...“This will bring competition to a market that has had very little competition for a long time,” said Paul Greenland, vice-president of biologics for Hospira....
...He finally landed a deal on Thursday with the $17bn takeover of Hospira. Who is Hospira?...
...The addition of Hospira brings Pfizer assets in two fast-growing areas....
...Morgan Stanley served as Hospira’s financial adviser, while Skadden, Arps, Slate, Meagher & Flom LLP was its legal adviser....
...In February, Pfizer bought Hospira, a US-based maker of generic drugs, for $17bn, a deal that some investors saw as an attempt to “fatten up” its established products division before splitting the group...
...Mr Read dismissed suggestions that Pfizer, which announced the $17bn purchase of Hospira earlier this year, had missed out on other attractive deals....
...deals that the bank has yet to be paid for are Heinz’s Kraft deal, which will create a $115bn consumer products giant, RockTenn’s $21bn packaging merger with MeadWestvaco and Pfizer’s $17bn acquisition of Hospira...
...Shares of Hospira, a maker of injectable drugs, was also one of the few stocks to rise, gaining 0.4 per cent to $89.85, after Pfizer received approval from the US Federal Trade Commission to acquire the...
...Pfizer made a big commitment to the category in February when it bought Hospira, a biosimilar manufacturer, for $17bn....
...The growth that Hospira brings could make Pfizer’s Established segment more attractive as a standalone company. Hospira does not come cheap....
International Edition